登录 | 注册    关注公众号  
微信公众号
搜索
>产品&服务 > 过表达及报告基因细胞株-ADC 药物筛选以及功能评价
过表达及报告基因细胞株-ADC 药物筛选以及功能评价

过表达及报告基因细胞株-ADC 药物筛选以及功能评价

抗体偶联药物(ADC)通过抗体(或抗体片段)与细胞毒性药物(Payload)通过连接子(Linker)形成的一种具有独特靶向性和高杀伤力的药物。ADC与肿瘤细胞表面抗原结合后内化进入细胞,在肿瘤细胞内释放细胞毒性药物,从而靶向杀伤肿瘤细胞,部分在胞内释放的细胞毒性药物被释放至肿瘤细胞外,通过旁观者效应进一步杀伤临近的肿瘤细胞。此外,ADC的抗体部分亦可以通过抑制靶抗原功能以及抗体介导的免疫反应等方式杀伤或抑制肿瘤细胞。
ACROBiosystems百普赛斯全面助力ADC药物研发,在原有的靶点蛋白业务基础上推出ADCC/APCP功能验证报告基因细胞株以及过表达细胞株产品。其中,ADCC/ADCP功能验证报告基因细胞株覆盖全部已知的FcγR基因型,用于ADC药物细胞水平的Fc功能评估;过表达细胞株基于成熟的细胞构建平台开发,可应用于ADC药物靶细胞杀伤验证,致力于为您提供更加全面的ADC药物质量表征解决方案!

ADC靶点蛋白过表达细胞株

在ADC药物的研发过程中,选择合适的靶抗原是基础,其特异性和表达水平的高低直接影响药物的疗效。在此基础上,抗体及ADC药物的筛选是研发的重要环节,筛选出的抗体需具备高亲和力、强内化能力、低免疫原性,并能在体内保持较长的半衰期。通过体外实验,可评估ADC药物对肿瘤细胞的杀伤效果、正常细胞的毒性以及是否具备旁观者效应等。

应用场景:

ADC靶点特异性及抗体亲和力筛选验证、作用机制研究、CMC质控、ADC药物靶细胞杀伤验证等

产品优势:

基于成熟的细胞构建平台开发,经过严格筛选和验证;

可稳定传代>20代,确保实验结果的可靠性。

产品列表:

分子 货号 产品描述
B7-H3 (4Ig) SCCHO-ATP169 CHO/Human B7-H3 (4Ig) Stable Cell Line Development Service
B7-H4 CHEK-ATP126 HEK293/Human B7-H4 Stable Cell Line
Cadherin-17 CHEK-ATP173 HEK293/Human Cadherin-17 Stable Cell Line
Cadherin-6 CHEK-ATP127 HEK293/Human Cadherin-6 Stable Cell Line
CCR8 CHEK-ATP140 HEK293/Human CCR8 Stable Cell Line
CD20 CHEK-ATP034 HEK293/Human CD20 Stable Cell Line
CD79A & CD79B SCCHO-ATP170 CHO/Human CD79A&CD79B Stable Cell Line Development Service
CD79B SCCHO-ATP171 CHO/Human CD79B Stable Cell Line Development Service
CEACAM-5 SCCHO-ATP081 CHO/Human CEACAM5 Stable Cell Line Development Service
CEACAM-5 CHEK-ATP083 HEK293/Human CEACAM5 Stable Cell Line
Claudin-1 CHEK-ATP124 HEK293/Human Claudin-1 Stable Cell Line
Claudin-18.2 CHEK-ATP033 HEK293/Human Claudin-18.2 Stable Cell Line
DLL3 CHEK-ATP090 HEK293/Human DLL3 Stable Cell Line
DLL3 SCCHO-ATP111 CHO/Human DLL3 Stable Cell Line Development Service
EGF R CHEK-ATP148 HEK293/Human EGF R Stable Cell Line
ENPP3 CHEK-ATP122 HEK293/Human ENPP3 Stable Cell Line
EpCAM CHEK-ATP175 HEK293/Human EpCAM Stable Cell Line
ErbB3 CHEK-ATP149 HEK293/Human ErbB3 Stable Cell Line
FAP CHEK-ATP184 HEK293/Human FAP Stable Cell Line
FOLR1 CHEK-ATP091 HEK293/Human FOLR1 Stable Cell Line
Glypican 3 CHEK-ATP092 HEK293/Human Glypican-3 (GPC3) Stable Cell Line
Glypican 3 SCCHO-ATP112 CHO/Human Glypican-3 (GPC3) Stable Cell Line
Glypican-3 SCCHO-ATP179 CHO/Cynomolgus Glypican-3 (GPC3) Stable Cell Line Development Service
GPRC5D CHEK-STP042 HEK293/Human GPRC5D Stable Cell Line
GPRC5D CCHO-STP078 CHO/Human GPRC5D Stable Cell Line
GUCY2C CHEK-ATP182 HEK293/Human GUCY2C Stable Cell Line
Her2 CHEK-ATP150 HEK293/Human ErbB2 Stable Cell Line
HGF R SCCHO-ATP141 CHO/Human c-MET Stable Cell Line Development Service
Integrin alpha V beta 6 CHEK-ATP125 HEK293/Human Integrin alpha V beta 6 Stable Cell Line
LRRC15 CHEK-ATP123 HEK293/Human LRRC15 Stable Cell Line
LY6G6D CHEK-ATP137 HEK293/Human LY6G6D Stable Cell Line
Mesothelin CHEK-ATP119 HEK293/Human Mesothelin Stable Cell Line
Mesothelin SCCHO-ATP120 CHO/Human Mesothelin Stable Cell Line Development Service
NAPI-IIb CHEK-ATP116 HEK293/Human NAPI-IIb Stable Cell Line
Nectin-4 CHEK-ATP035 HEK293/Human Nectin-4 Stable Cell Line
PD-L1 SCRAJ-STT075 Raji/Human PD-L1 Stable Cell Line Development Service
PD-L1 SCCHO-ATP077L CHO/Human PD-L1 Stable Cell Line (Low Expression) Development Service
PD-L1 SCCHO-ATP077M CHO/Human PD-L1 Stable Cell Line (Medium Expression) Development Service
PD-L1 SCCHO-ATP077H CHO/Human PD-L1 Stable Cell Line (High Expression) Development Service
PSMA CHEK-ATP185 HEK293/Human PSMA Stable Cell Line
PTK7 CHEK-ATP186 HEK293/Human PTK7 Stable Cell Line
ROR1 CHEK-ATP084 HEK293/Human ROR1 Stable Cell Line
ROR1 SCCHO-ATP083 CHO/Human ROR1 Stable Cell Line Development Service
SEZ6 CHEK-ATP183 HEK293/Human SEZ6 Stable Cell Line
STEAP1 CHEK-ATP100 HEK293/Human STEAP1 Stable Cell Line
STEAP1 SCCHO-ATP121 CHO/Human STEAP1 Stable Cell Line Development Service
TPBG CHEK-ATP176 HEK293/Human TPBG Stable Cell Line
Transferrin CHEK-ATP115 HEK293/Human Transferrin Stable Cell Line
Transferrin R CHEK-ATP089 HEK293/Human Transferrin R Stable Cell Line
TROP-2 CHEK-ATP036 HEK293/Human TROP-2 Stable Cell Line
uPAR SCCHO-ATP152 CHO/Human uPAR Stable Cell Line Development Service
uPAR CHEK-ATP151 HEK293/Human uPAR Stable Cell Line

点击查看更多过表达细胞株产品 >>>

验证数据:

Nectin-4过表达细胞株活性验证-FACS
Nectin-4过表达细胞株活性验证-FACS

FACS analysis of Nectin-4 on HEK293/Human Nectin-4 Stable Cell Line.
FACS assay shows that Anti-Nectin-4 antibody can bind to HEK293/Human Nectin-4 Stable Cell Line (Cat. No. CHEK-ATP035). HEK293/Human Nectin-4 stable cells was red line, Negative control HEK293 cells was grey line (QC tested).

申请 Protocol
TROP-2过表达细胞株活性验证-FACS
TROP-2过表达细胞株活性验证-FACS

FACS assay shows that Anti-TROP-2 antibody can bind to HEK293/Human TROP-2 Stable Cell Line.
HEK293/Human TROP-2 stable cells (Cat. No. CHEK-ATP036) was red line, Negative control HEK293 cells was grey line (QC tested).
 

申请 Protocol

ADCC/ADCP功能验证报告基因细胞株

ADC药物还可利用Fc介导的效应功能实现对肿瘤细胞的杀伤和清除,例如抗体依赖性细胞介导的细胞毒作用(ADCC)、补体依赖性细胞毒作用(CDC) 和抗体依赖性细胞吞噬作用 (ADCP)。
在ADCC过程中,ADC药物的Fab端与靶细胞表面的抗原结合,同时其Fc部分与免疫效应细胞(如NK细胞)表面的FcγR结合,激活免疫效应细胞释放细胞毒性物质,从而杀死靶细胞。而在ADCP过程中,ADC药物的Fc部分与肿瘤相关巨噬细胞(TAM)表面的FcγR结合,激活巨噬细胞产生吞噬作用,将靶细胞吞噬并降解。因此,评估ADC药物的ADCC/ADCP效应对于确保药物的安全性和有效性至关重要。
ACROBiosystems百普赛斯推出ADCC / ADCP功能验证报告基因细胞株。通过基因工程改造,在Jurkat细胞内转入一个受NFAT信号调控驱动的Luciferase报告基因,同时使其在细胞膜表面表达一种FcγR。当将该细胞与靶细胞和相关抗体共培养时,抗体同时结合靶细胞抗原和该细胞表面Fcγ受体,导致受体聚集、细胞内信号传导和NFAT介导的Luciferase 报告基因表达与发光。
培养扩增

应用场景:

评估ADC药物的ADCC/ADCP效应

产品优势:

FcγR家族全覆盖,不同基因型可供选择;

选用Jurkat细胞构建,模拟真实免疫细胞状态;

采用荧光素酶(Luc)报告基因系统,反应信号强,检测窗口大,灵敏度高;

经代次稳定性验证,可稳定传代>20代,利于方法学验证;

经商业化抗体验证,应用场景明确;

售前免费样本测试,售后专业技术支持团队+无忧售后政策保障 点击查看ACRO兜底售后政策;

为客户IND申报提供支持文件。

产品列表:

应用 分子 货号 产品描述
ADCP Fc gamma RIIA / CD32a SCJUR-STF069 Human CD32a (131H) (Luc) Jurkat Reporter Cell Development Service
Fc gamma RIIA / CD32a SCJUR-STF070 Human CD32a (131R) (Luc) Jurkat Reporter Cell Development Service
Fc gamma RIIB / CD32b SCJUR-STF071 Human CD32b (Luc) Jurkat Reporter Cell Development Service
Fc gamma RI / CD64 SCJUR-STF072 Human CD64 (Luc) Jurkat Reporter Cell Development Service
ADCC Fc gamma RIIIA / CD16a SCJUR-STF067 Human CD16a (158V) (Luc) Jurkat Reporter Cell Development Service
Fc gamma RIIIA / CD16a SCJUR-STF068 Human CD16a (158F) (Luc) Jurkat Reporter Cell Development Service

点击查看更多报告基因细胞株产品 >>>

验证数据:

ADCC活性评价应用案例

Human CD16a (158V) (Luc) Jurkat Reporter Cell Development Service (Cat.No. SCJUR-STF067)

Human CD16a (158V) (Luc) Jurkat Reporter Cell Development Service (Cat.No. SCJUR-STF067)

ADCC response to anti-human CD20 antibody (RLU). Anti-human CD20 antibody-induced ADCC activity was evaluated using Human CD16a (158V) (Luc) Jurkat Reporter Cell in the presence of Raji cells that express CD20 endogenously. The EC50 of anti-human CD20 antibody was approximately 0.0028 μg/mL.

申请 Protocol
Human CD16a (158V) (Luc) Jurkat Reporter Cell Development Service (Cat.No. SCJUR-STF067)

ADCC response to anti-human CD20 antibody (FOLD). Anti-human CD20 antibody-induced ADCC activity was evaluated using Human CD16a (158V) (Luc) Jurkat Reporter Cell in the presence of Raji cells that express CD20 endogenously. The max induction fold was approximately 854.

申请 Protocol
ADCP活性评价应用案例

Human CD32a (131H) (Luc) Jurkat Reporter Cell Development Service (Cat.No. SCJUR-STF069)

Human CD32a (131H) (Luc) Jurkat Reporter Cell Development Service (Cat.No. SCJUR-STF069)

ADCP response to anti-human CD20 antibman CD20 antibody-induced ADCP activity was evaluated using Human CD32a (131H) (Luc) Jurkat Reody (RLU). Anti-huporter Cell in the presence of Raji cells that express CD20 endogenously. The EC50 was approximately 0.1054 μg/mL.

申请 Protocol
Human CD32a (131H) (Luc) Jurkat Reporter Cell Development Service (Cat.No. SCJUR-STF069)

ADCP response to anti-human CD20 antibody (FOLD). Anti-human CD20 antibody-induced ADCP activity was evaluated using Human CD32a (131H) (Luc) Jurkat Reporter Cell in the presence of Raji cells that express CD20 endogenously. The max induction fold was approximately 277.90.

申请 Protocol
ADCC / ADCP细胞株表达验证-FACS

Human CD16a (158V) (Luc) Jurkat Reporter Cell Development Service (Cat.No. SCJUR-STF067)

Human CD16a (158V) (Luc) Jurkat Reporter Cell Development Service (Cat.No. SCJUR-STF067)

Expression analysis of human CD16a (158V) on Human CD16a (158V) (Luc) Jurkat Reporter Cell by FACS. Human CD16a (158V) (Luc) Jurkat Reporter Cell or negative control cell were stained with PE-labeled anti-human CD16a antibody.

申请 Protocol

Human CD32a (131H) (Luc) Jurkat Reporter Cell Development Service (Cat.No. SCJUR-STF069)

Human CD32a (131H) (Luc) Jurkat Reporter Cell Development Service (Cat.No. SCJUR-STF069)

Expression analysis of human CD32a on Human CD32a (131H) (Luc) Jurkat Reporter Cell by FACS. Cell surface staining was performed on Human CD32a (131H) (Luc) Jurkat Reporter Cell or negative control cell using PE-labeled anti-human CD32a antibody.

申请 Protocol
ADCC /ADCP细胞株次代稳定性验证

Human CD16a (158V) (Luc) Jurkat Reporter Cell Development Service (Cat.No. SCJUR-STF067)

Human CD16a (158V) (Luc) Jurkat Reporter Cell Development Service (Cat.No. SCJUR-STF067)

Passage stability analysis by Signaling Bioassay. The continuously growing Human CD16a (158V) (Luc) Jurkat Reporter Cell was stimulated with serial dilutions of anti-human CD20 antibody in the presence of Raji cells that express CD20 endogenously. Anti-human CD20 antibody stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 14-26.

申请 Protocol

Human CD32a (131H) (Luc) Jurkat Reporter Cell Development Service (Cat.No. SCJUR-STF069)

Human CD32a (131H) (Luc) Jurkat Reporter Cell Development Service (Cat.No. SCJUR-STF069)

Passage stability analysis by Signaling Bioassay. The continuously growing Human CD32a (131H) (Luc) Jurkat Reporter Cell was stimulated with serial dilutions of Anti-human CD20 antibody in the presence of Raji cells. Anti-human CD20 antibody stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 10-23.

申请 Protocol
ACRO质量管理体系

消息提示

请输入您的联系方式,再点击提交!

确定